| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Eli Lilly is experiencing robust growth in product and service development, particularly with advancements in treatments for atopic dermatitis and promising clinical data for various therapies. The company is set to launch new drugs internationally, reflecting strong market potential and innovative approaches to obesity and other medical conditions. Significant progress in medical advancements enhances confidence in their offerings. Overall, the momentum in product development is expected to positively influence Eli Lilly's future performance. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.2, and the negative at -0.2 on 2025-03-13. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (1.1) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| LLY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-13 | 0%(0%) | 0 | 0% | 0 | 1.1 | -1 | |||||||
| 2025-03-12 | 0%(0%) | 0 | 0% | -0.1 | 0.7 | -1 | |||||||
| 2025-03-06 | 0%(0%) | 0 | 0% | 0.1 | 1.4 | -1 | |||||||
| 2025-02-25 | 0%(0%) | 0 | 0% | 0.1 | 1.6 | -1 | |||||||
| 2025-02-23 | 0%(0%) | 0 | 0% | 0.2 | 2.1 | -1 | |||||||
| 2025-02-18 | 0%(0%) | 0 | 0% | 0.2 | 2.4 | -1 | |||||||
| 2025-02-14 | 0%(0%) | 0 | 0% | 0.2 | 2.3 | -1 | |||||||
| 2025-02-12 | 0%(0%) | 0 | 0% | 0.2 | 2.2 | -1 | |||||||
| 2025-02-11 | 0%(0%) | 0 | 0% | 0.3 | 2.9 | -1 | |||||||
| 2025-02-10 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-05-19 17:10:45 The collaboration due to the licensing of GUBamy signifies strategic partnerships in the healthcare industry to enhance product offerings. |
| 2025-05-19 17:10:45 With features like better GI tolerability and cardiovascular safety, GUBamy may provide AbbVie with competitive advantages in the obesity treatment sector. |
| 2025-05-19 17:10:45 The significant upfront payment for GUBamy demonstrates AbbVie's commitment to diversifying its portfolio through strategic investments. |
| 2025-05-19 17:10:45 AbbVie is entering the obesity market with innovative therapies, such as GUBamy, reflecting ongoing development in this area. |
| 2025-05-19 17:10:45 The competitive landscape in the obesity treatment market is intensifying, with AbbVie looking to challenge established players like Eli Lilly and Novo Nordisk. |